Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Declines By 19.4%

Nanobiotix S.A. (NASDAQ:NBTX) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 40,600 shares, a drop of 19.4% from the August 31st total of 50,400 shares. Based on an average daily trading volume, of 9,600 shares, the short-interest ratio is currently 4.2 days.

Nanobiotix Trading Up 7.7 %

NASDAQ:NBTX traded up $0.38 during trading hours on Friday, reaching $5.33. The company had a trading volume of 940 shares, compared to its average volume of 19,358. The business’s 50-day simple moving average is $5.15 and its two-hundred day simple moving average is $5.68. Nanobiotix has a twelve month low of $4.14 and a twelve month high of $9.34.

Wall Street Analyst Weigh In

Separately, Guggenheim assumed coverage on shares of Nanobiotix in a research note on Wednesday, August 28th. They set a “buy” rating and a $12.00 target price for the company.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.